The reasons for this, on one hand, is that Glaucoma and Diabetic Retinopathy disorders are chronic problems that after diagnosis almost always require treatment and on another hand, their medicines and treatments such as Laser therapy and anti-vascular endothelial growth factor drugs injection are very costly that impose high ocular OOP expenditure on the patients (22). The gene discussed is VEGFA; the disease is glaucoma.